New treatment for inflammatory bowel disease lands Microbiotica €42 million
Microbiotica, a British clinical-stage biopharma company developing a pipeline of orally-dosed, precision microbiome medicines, today announces the first close of a €42 million (£36 million) Series C financing. The financing was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners. All existing Series B…
We haven't written up this one. EU-Startups has the full story — the link below goes straight to it.
